News
gla_wpadmin  

OTS: Grifols / Strategic transaction progress: Grifols achieves …

Progress on strategic transaction: Grifols achieves high

Acceptance of his takeover bid for Biotest

Barcelona, ​​Spain (ots) –

– After the deadline for accepting the public takeover bid

(Public Takeover Offer – PTO) for Biotest shares, Grifols has

96% of the voting rights and holds 69.7% of the share capital. The public

Takeover offer was accepted by 43.2% of preferred shares.

– The PTO put period for the remaining common shares ends on April 21, 2022.

– The completion of the transaction depends on various regulatory

Permissions and Conditions.

– The acquisition will increase the availability of plasma therapies and

ensure better access to patients. Grifols’ market position is through

Promotion and expansion of its product portfolio and the diversification of its

presence strengthened. So the company can increase its growth and profitability

improve.

– New proteins, including IgM and fibrinogen, and synergy effects are supposed to

Driving revenue growth and margin expansion: more than 7 billion

Euro combined sales, more than 2 billion Euro EBITDA, an EBITDA margin

of over 30% and leverage of less than 3.5x by 2024.

Grifols is making further progress with the takeover of Biotest AG. the

strategic transaction will help improve the plasma supply of Grifols

to expand and diversify the business operations and revenues in

Europe, the Middle East and Africa to strengthen and economic success

of the company to advance. Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS) is

a world leader in the manufacture of plasma-derived

Medicines that have been helping to improve health and… for more than 110 years

improve people’s well-being.

As of today, following the agreement to acquire the

total share capital of Tiancheng (Germany) Pharmaceutical Holdings AG and

the end of the acceptance period for the public takeover offer (PTO) for the

remaining shares a degree of acceptance of its PTO to Biotest of 96.2%

Voting rights achieved and holds 69.72% of the share capital. The offer was made by

accepted the 43.24% of the preferred shares.

After expiry of the grace period for acceptance of the public takeover bid

exists for the remaining non-controlled (voting)

Common shares have an additional acceptance period of three months until April 21

2022, as the 95% control limit was exceeded.

Taking into account the agreement with Tiancheng (Germany) Pharmaceutical

Holdings AG and the PTO acceptance initiated for all remaining shares

today, Grifols holds 19,034,074 ordinary shares (with voting rights) and 8,555,158

Preference shares (non-voting), representing 48.10% and 21.62% of the share capital of

Biotest AG corresponds.

The investment in Biotest strengthens the scientific and industrial

performance of Grifols and contributes to the availability of

Plasma drugs, the market presence and the project portfolio in research and

improve development.

Join forces for the benefit of patients

With this transaction, Grifols and Biotest are making progress together to

To increase the availability of plasma therapies worldwide.

In September 2021, Grifols agreed to acquire the entire share capital of

Tiancheng (Germany) Pharmaceutical Holdings AG holding 90% of the common shares and 1%

who owns preferred shares of Biotest AG, for 1.1 billion euros. This amount

includes a loan receivable received from Tiancheng (Germany) Pharmaceutical

Holdings was granted to Biotest AG in the amount of around EUR 313 million.

In December 2021, the Management Board and the Supervisory Board of Biotest recommended that

to accept a takeover offer from Grifols. Both panels came to the conclusion

that the business combination of Grifols and Biotest is an opportunity

represents increasing the availability of plasma therapies and the

Promote new product development and R&D projects.

After opening two new centres, Biotest currently has 28

Plasma donation centers in Europe. In addition, this complementary investment will

Increase success of Grifols:

· Improving profitability and sales per liter of plasma through the

Leveraging currently unused proteins and Grifols’ global network

Plasmazentren

· Noticeable increase in sales and profit margins from 2023 due to new

product launches

· Significant revenue and cost synergies for development, manufacturing and

the distribution of plasma-derived therapies

· Accelerated product development pipeline

· Greater geographical balance in plasma supply and revenue

· With more than 20 million liters of plasma in 2021, Grifols will have a

have leading capacity within the industry

· By 2024, Grifols forecasts combined sales of more than 7

billion euros, an EBITDA of more than 2 billion euros, an EBITDA margin

of more than 30% and a gearing ratio of less than 3.5x

The transaction is subject to various regulatory approvals and

conditions and is expected to be completed by the end of the first half of 2022

to be finished.

NOTE: The public takeover offer can be found at

https://www.grifols.com/es/biotest-voluntary-takeover-offer

(in German and in a non-binding English translation).

About Grifols

Grifols is a global healthcare company that has been working since 1909 to

the health and well-being of people around the world

improve. Its four business areas – Bioscience, Diagnostic, and Hospital

Bio Supplies – develop, produce and market innovative solutions and

Services in more than 100 countries.

As a pioneer in the blood products industry, Grifols is one of the largest

plasma company and has a growing network of donation centers in

all over the world. With the plasma obtained, Grifols provides important medicines

treatment of chronic, rare and sometimes very serious diseases. When

recognized market leader in transfusion medicine, the company has

a comprehensive portfolio of solutions that ensure security from donation to

improve transfusion. In addition, the company provides hospitals,

Pharmacies and health professionals resources, information and

Services available to help provide a specialized and

provide efficient medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions

committed to a sustainable business model that helps to

Standards for continuous innovation, quality, safety and ethical

to define leadership in this sector.

In 2020, the macroeconomic impact of Grifols in the

most important countries in which the company operates, to a total of 7.5

billion euros and 140,000 jobs estimated, including direct,

indirect and induced jobs.

The Company’s common stock (Class A) will be issued on the Spanish

continuous market and are part of the Ibex-35 (MCE: GRF). the

non-voting shares (class B) of Grifols are in the Spanish

continuous market (MCE: GRF.P) and on the North American NASDAQ via

ADR (American Depositary Receipts) (NASDAQ: GRFS) notiert.

For more information: https://www.grifols.com

—————————-

DISCLAIMER

The facts and figures contained in this report, which do not relate to

historical data are “forward projections and assumptions”. words and

Expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”,

“intend”, “should”, “aim”, “estimate”, “future” and

similar expressions as they relate to the Grifols Group

used to identify future projections and assumptions. This

Expressions reflect the assumptions, hypotheses, expectations and predictions of the

Management teams at the time of writing this report that one

set of factors that lead to the actual

Results may vary significantly. The future results of

Grifols Group could be affected by events related to their

own activities related, such as a lack of raw materials for the

manufacture of their products, the appearance of competing products on the market

or changes in the regulatory framework in the markets in which they operate

is to name a few. At the time of writing this report

the Grifols Group has taken the necessary measures to address the potential

mitigate the impact of these events. Grifols SA does not accept any

Obligation to publish future projections or assumptions, to revise them

or update them to reflect events or circumstances after the date of

Customize this report unless required by applicable law

legislation expressly required. This document sets neither

Offer nor an invitation to purchase or subscribe for Shares pursuant to the

provisions of the following Spanish legislation: Royal

Legislative Decree 4/2015 of October 23 approving the recast of the

Securities Market Act; Royal Decree Law 5/2005 of 11.

March and/or Royal Decree 1310/2005 of November 4 and all

Regulations to further develop these laws. In addition, this

Do not document any offer to buy, sell or exchange, or any solicitation

an offer to buy, sell or exchange securities or

Request for a vote or approval in another jurisdiction

The information contained in this document was obtained from the external

neither checked nor checked by the auditors of the Grifols Group.

Press contact:

Investor Relations:

mailto:[email protected]

mailto: [email protected]

Tel. +34 93 571 02 21

Media contacts:

Duomo Communication – Grifols Pressestelle

Rachel Lumbreras

mailto:[email protected]

borja gomez

mailto: [email protected]

Tel. +34 91 311 92 89 – 91 311 92 90

Grifols Press Office Spain

mailto: [email protected]

Tel. +34 571 00 02

Grifols Press Office Germany

Rudiger Litzba

mailto:[email protected]

Tel. +49 6172 265 97 12

Further material: http://presseportal.de/pm/62216/5131228

OTS: Grifols

Reference-www.finanzen.at

Leave A Comment